Effect of propranolol on secretin-induced gastrin release and secretin-induced tachycardia in patients with the Zollinger-Ellison syndrome

Aliment Pharmacol Ther. 1990 Aug;4(4):325-31. doi: 10.1111/j.1365-2036.1990.tb00479.x.

Abstract

The mechanism for secretin-induced gastrin release in the Zollinger-Ellison syndrome is uncertain. We evaluated whether the stimulatory effect of intravenous secretin on gastrin release was partly mediated through a beta-adrenergic stimulatory mechanism. Serum gastrin concentrations and heart rate were monitored in six patients with the Zollinger-Ellison syndrome. Secretin (2 clinical units/kg) increased mean serum gastrin concentrations from 1558 pg/ml basally to a peak of 3683 pg/ml (136% above baseline). This increase was not altered by pretreatment with 2 mg of propranolol intravenously, a dose which in previous studies blocked terbutaline-induced gastrin release. Secretin increased heart rate by 14 beats/min (20% above base-line) and this also was not altered by propranolol pretreatment. Thus, the stimulatory effects of secretin on gastrinoma cells and the heart do not appear to be mediated by beta-adrenergic receptors.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Gastrins / blood
  • Gastrins / metabolism*
  • Heart Rate / drug effects
  • Humans
  • Male
  • Middle Aged
  • Propranolol / pharmacology*
  • Radioimmunoassay
  • Secretin / antagonists & inhibitors*
  • Secretin / pharmacology
  • Tachycardia / etiology*
  • Tachycardia / physiopathology
  • Zollinger-Ellison Syndrome / drug therapy*
  • Zollinger-Ellison Syndrome / physiopathology

Substances

  • Gastrins
  • Secretin
  • Propranolol